Abbvie Inc
NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024
ABBV Articles
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Dana, Humana, International Paper, Navistar, Southwest Airlines and Tesla.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Apple, Broadcom, Exxon Mobil, Fabrinet, HP, Match and Target.
Published:
Last Updated:
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
AbbVie is trying one of the older and less-used efforts to drive its share price back up: a modified Dutch tender auction.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Published:
Last Updated:
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Monday was an incredible day for the broad U.S. markets, with the Dow posting one of its top 3 performances, in terms of points, in the history of the average. The S&P 500 and Nasdaq had...
Published:
Last Updated:
AbbVie shares took a big step back last week after the firm reported less than favorable results for its relapsed/refractory small cell lung cancer trial.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron Technology, Nike and Occidental Petroleum.
Published:
Last Updated:
Thursday was an absolute disaster for the broad U.S. markets. There didn’t seem to be anything positive about Thursday for any of the major indices. The Dow was the biggest loser of the group, it...
Published:
Last Updated: